European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
出版年份 2016 全文链接
标题
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
作者
关键词
-
出版物
LEUKEMIA
Volume 30, Issue 8, Pages 1648-1671
出版商
Springer Nature
发表日期
2016-04-28
DOI
10.1038/leu.2016.104
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
- (2016) A Hochhaus et al. LEUKEMIA
- Cardiovascular and pulmonary adverse events in patients treated withBCR-ABLinhibitors: Data from the FDA Adverse Event Reporting System
- (2015) Jorge Cortes et al. AMERICAN JOURNAL OF HEMATOLOGY
- Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia
- (2015) Delphine Rea ANNALS OF HEMATOLOGY
- Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina
- (2015) Jianxiang Wang et al. BLOOD
- Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors
- (2015) J S L Kloth et al. BRITISH JOURNAL OF CANCER
- Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV
- (2015) L Kalmanti et al. LEUKEMIA
- Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study
- (2015) A Hochhaus et al. LEUKEMIA
- Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months
- (2015) Luis-Felipe Casado et al. Cancer Medicine
- Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia
- (2014) Carlo Gambacorti-Passerini et al. AMERICAN JOURNAL OF HEMATOLOGY
- Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV
- (2014) Ulrike Proetel et al. ANNALS OF HEMATOLOGY
- Interaction of platelet-derived autotaxin with tumor integrin V 3 controls metastasis of breast cancer cells to bone
- (2014) R. Leblanc et al. BLOOD
- Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study
- (2014) N. P. Shah et al. BLOOD
- Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors
- (2014) P. Valent et al. BLOOD
- Bosutinibversusimatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial
- (2014) Tim H. Brümmendorf et al. BRITISH JOURNAL OF HAEMATOLOGY
- Patient-reported outcomes in acute leukemia: a roadmap for future research
- (2014) Fabio Efficace et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Rapid onset of peripheral artery disease in a chronic myeloid leukemia patient without prior arterial disorder: direct relationship with nilotinib exposure and clinical outcome
- (2014) Tristan Mirault et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia
- (2014) D. Rea et al. HAEMATOLOGICA
- Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study
- (2014) Michele Baccarani et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Hypopigmented macules secondary to imatinib for the treatment of chronic myeloid leukemia: a histopathologic and immunohistochemical study
- (2014) Mar Llamas-Velasco et al. JOURNAL OF CUTANEOUS PATHOLOGY
- Usefulness of the 2012 European CVD risk assessment model to identify patients at high risk of cardiovascular events during nilotinib therapy in chronic myeloid leukemia
- (2014) D Rea et al. LEUKEMIA
- Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib
- (2013) Paul La Rosée et al. ANNALS OF HEMATOLOGY
- European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
- (2013) M. Baccarani et al. BLOOD
- How I treat leukemia during pregnancy
- (2013) D. Milojkovic et al. BLOOD
- Autocrine TNF- production supports CML stem and progenitor cell survival and enhances their proliferation
- (2013) P. Gallipoli et al. BLOOD
- Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling
- (2013) H. de Lavallade et al. BLOOD
- Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)
- (2013) E. Jabbour et al. BLOOD
- Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia
- (2013) Michael W. Deininger et al. BRITISH JOURNAL OF HAEMATOLOGY
- Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies
- (2013) Daryl Sonnichsen et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Dasatinib, large granular lymphocytosis, and pleural effusion: Useful or adverse effect?
- (2013) Semra Paydas CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Hepatotoxicity of Tyrosine Kinase Inhibitors: Clinical and Regulatory Perspectives
- (2013) Rashmi R. Shah et al. DRUG SAFETY
- Tyrosine Kinase Inhibitors: Their On-Target Toxicities as Potential Indicators of Efficacy
- (2013) Devron R. Shah et al. DRUG SAFETY
- Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in chronic myeloid leukemia: a single institution study
- (2013) Luciano Levato et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- The clinical impact of ponatinib on the risk of bleeding in patients with chronic myeloid leukemia
- (2013) A. Nazha et al. HAEMATOLOGICA
- Treatment with dasatinib for chronic myeloid leukemia following imatinib-induced hepatotoxicity
- (2013) Lars Harbaum et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Simultaneous manifestation of pleural effusion and acute renal failure associated with dasatinib: a case report
- (2013) G. Kaiafa et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- Management of Patients With Peripheral Artery Disease (Compilation of 2005 and 2011 ACCF/AHA Guideline Recommendations)
- (2013) Jeffrey L. Anderson et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Imatinib, dasatinib and nilotinib: a review of adverse cutaneous reactions with emphasis on our clinical experience
- (2013) V. Brazzelli et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Multiple eruptive dermatofibromas related to imatinib treatment
- (2013) M. Llamas-Velasco et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Fatal progressive cerebral ischemia in CML under third-line treatment with ponatinib
- (2013) K Mayer et al. LEUKEMIA
- Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib
- (2013) T D Kim et al. LEUKEMIA
- Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis
- (2013) F J Giles et al. LEUKEMIA
- Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitors
- (2013) Massimo Breccia et al. LEUKEMIA RESEARCH
- Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors
- (2013) Ellin Berman et al. LEUKEMIA RESEARCH
- A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
- (2013) J.E. Cortes et al. NEW ENGLAND JOURNAL OF MEDICINE
- High-Resolution Computed Tomography Findings for Patients With Drug-Induced Pulmonary Toxicity, With Special Reference to Hypersensitivity Pneumonitis-Like Patterns in Gemcitabine-Induced Cases
- (2013) M. Tamura et al. ONCOLOGIST
- The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists?
- (2012) Wing L. Ho et al. ACTA OPHTHALMOLOGICA
- Pharmacokinetics of nilotinib in imatinib-resistant/intolerant chronic myeloid leukemia patients on hemodialysis for chronic renal failure
- (2012) Takashi Onaka et al. AMERICAN JOURNAL OF HEMATOLOGY
- Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals?
- (2012) Fabio Efficace et al. ANNALS OF HEMATOLOGY
- Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure
- (2012) H. J. Khoury et al. BLOOD
- Hodgkin lymphoma requires stabilized NIK and constitutive RelB expression for survival
- (2012) S. M. Ranuncolo et al. BLOOD
- The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia
- (2012) A. Giannoudis et al. BLOOD
- A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia
- (2012) J. P. Radich et al. BLOOD
- Dasatinib inhibits proinflammatory functions of mature human neutrophils
- (2012) K. Futosi et al. BLOOD
- Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: A meta-analysis
- (2012) Yi Ling Teo et al. CANCER TREATMENT REVIEWS
- Pulmonary Arterial Hypertension in Patients Treated by Dasatinib
- (2012) David Montani et al. CIRCULATION
- Nilotinib-Associated Vascular Events
- (2012) Alfonso Quintás-Cardama et al. Clinical Lymphoma Myeloma & Leukemia
- Rash with the multitargeted kinase inhibitors nilotinib and dasatinib: meta-analysis and clinical characterization
- (2012) Aaron M. Drucker et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Platelet dysfunction associated with ponatinib, a new pan BCR-ABL inhibitor with efficacy for chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitor therapy
- (2012) P. Neelakantan et al. HAEMATOLOGICA
- Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial
- (2012) F. Guilhot et al. HAEMATOLOGICA
- Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia
- (2012) Roberto Latagliata et al. HEMATOLOGICAL ONCOLOGY
- Rapid and sustained increase of large granular lymphocytes and rare cytomegalovirus reactivation during dasatinib treatment in chronic myelogenous leukemia patients
- (2012) Hideo Tanaka et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial
- (2012) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study
- (2012) F J Giles et al. LEUKEMIA
- Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy
- (2012) S Mustjoki et al. LEUKEMIA
- Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up
- (2012) R A Larson et al. LEUKEMIA
- Off-target effects of BCR–ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia
- (2012) Juan Luis Steegmann et al. LEUKEMIA & LYMPHOMA
- Characteristics of, and risk factors for, infections in patients with cancer treated with dasatinib and a brief review of other complications
- (2012) Gilhen H. Rodriguez et al. LEUKEMIA & LYMPHOMA
- Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias
- (2012) Jorge E. Cortes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Choosing the right TKI for chronic myeloid leukemia: When the truth lies in “long-term” safety and efficacy
- (2011) Carlo Gambacorti-Passerini et al. AMERICAN JOURNAL OF HEMATOLOGY
- Retrospective multicenter study on the development of peripheral lymphocytosis following second-line dasatinib therapy for chronic myeloid leukemia
- (2011) Su Jin Lee et al. AMERICAN JOURNAL OF HEMATOLOGY
- Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML
- (2011) Karl J. Aichberger et al. AMERICAN JOURNAL OF HEMATOLOGY
- Nilotinib treatment-associated peripheral artery disease and sudden death: Yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia
- (2011) Ayalew Tefferi et al. AMERICAN JOURNAL OF HEMATOLOGY
- Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients
- (2011) M. S. Marcolino et al. ANNALS OF ONCOLOGY
- Activity and Safety of Dasatinib as Second-Line Treatment or in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients
- (2011) Massimo Breccia et al. BIODRUGS
- Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib
- (2011) J. E. Cortes et al. BLOOD
- Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population
- (2011) F. Efficace et al. BLOOD
- Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib
- (2011) J. E. Cortes et al. BLOOD
- Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
- (2011) H. M. Kantarjian et al. BLOOD
- Expanding Nilotinib Access in Clinical Trials (ENACT)
- (2011) Franck E. Nicolini et al. CANCER
- A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects
- (2011) Richat Abbas et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Physician’s guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML
- (2011) Gianantonio Rosti et al. CANCER TREATMENT REVIEWS
- Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib
- (2011) IRIS AMITAY-LAISH et al. Dermatologic Therapy
- Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia
- (2011) D. Dumitrescu et al. EUROPEAN RESPIRATORY JOURNAL
- Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib
- (2011) M. Breccia et al. HAEMATOLOGICA
- Long-term pattern of pleural effusion from chronic myeloid leukemia patients in second-line dasatinib therapy
- (2011) Dongho Kim et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-α in Newly Diagnosed Chronic Myeloid Leukemia
- (2011) Rüdiger Hehlmann et al. JOURNAL OF CLINICAL ONCOLOGY
- Peripheral neuropathy as an adverse effect of imatinib therapy
- (2011) Geothy Chakupurakal et al. JOURNAL OF CLINICAL PATHOLOGY
- Nilotinib Attenuates Renal Injury and Prolongs Survival in Chronic Kidney Disease
- (2011) M. Iyoda et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib
- (2011) Carlo Gambacorti-Passerini et al. JNCI-Journal of the National Cancer Institute
- Severe Peripheral Arterial Disease During Nilotinib Therapy
- (2011) P. Le Coutre et al. JNCI-Journal of the National Cancer Institute
- Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial
- (2011) Hagop M Kantarjian et al. LANCET ONCOLOGY
- Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation
- (2011) A Kreutzman et al. LEUKEMIA
- Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis
- (2011) Franck E. Nicolini et al. LEUKEMIA & LYMPHOMA
- Evaluation of tolerability and efficacy of imatinib mesylate in elderly patients with chronic phase CML: ELDERGLI study
- (2011) Fermin M. Sánchez-Guijo et al. LEUKEMIA RESEARCH
- LOW INCIDENCE RATE OF OPPORTUNISTIC AND VIRAL INFECTIONS DURING IMATINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS IN EARLY AND LATE CHRONIC PHASE
- (2011) Massimo Breccia et al. Mediterranean Journal of Hematology and Infectious Diseases
- CML: how low can you go?
- (2010) C. A. Schiffer BLOOD
- Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results
- (2010) H. M. Kantarjian et al. BLOOD
- Activity and tolerability of nilotinib
- (2010) Maya Koren-Michowitz et al. CANCER
- Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors
- (2010) Faye M. Johnson et al. CANCER
- Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study
- (2010) Giuseppe Saglio et al. CANCER
- Practical management of tyrosine kinase inhibitor-associated side effects in GIST
- (2010) Heikki Joensuu et al. CANCER TREATMENT REVIEWS
- Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib
- (2010) N. P. Shah et al. HAEMATOLOGICA
- The duration of the use of imatinib mesylate is only weakly related to elevated BNP levels in chronic myeloid leukaemia patients
- (2010) Milena S. Marcolino et al. HEMATOLOGICAL ONCOLOGY
- The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity
- (2010) Julia Salih et al. INTERNATIONAL JOURNAL OF CANCER
- Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion
- (2010) Yasunobu Nagata et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Nilotinib in a Patient With Postnecrotic Liver Cirrhosis Related to Imatinib
- (2010) Vito Spataro JOURNAL OF CLINICAL ONCOLOGY
- Tumor lysis syndrome during treatment with AMN107 (Nilotinib) in a patient with chronic myelogenous leukemia accelerated phase
- (2010) M. Sonmez et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- The use of imatinib mesylate has no adverse effects on the heart function. Results of a pilot study in patients with chronic myeloid leukemia
- (2010) Milena Soriano Marcolino et al. LEUKEMIA RESEARCH
- Reversible hair depigmentation in a patient treated with imatinib
- (2010) Stefania Mariani et al. LEUKEMIA RESEARCH
- A prospective evaluation of cardiac function in patients with chronic myeloid leukaemia treated with imatinib
- (2010) Zahra Raisi Estabragh et al. LEUKEMIA RESEARCH
- Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia
- (2010) Claude Preudhomme et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
- (2010) Hagop Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
- (2010) Giuseppe Saglio et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acute Renal Failure under Dasatinib Therapy
- (2010) Sultan Ozkurt et al. RENAL FAILURE
- Thyroid Dysfunction Caused by Second-Generation Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
- (2010) Theo D. Kim et al. THYROID
- Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice
- (2010) Nicole M Agostino et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Cardiotoxicity induced by tyrosine kinase inhibitors
- (2009) George S. Orphanos et al. ACTA ONCOLOGICA
- Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party
- (2009) F. Castagnetti et al. BLOOD
- Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia
- (2009) A. Quintas-Cardama et al. BLOOD
- Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia
- (2009) G. Rosti et al. BLOOD
- The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo
- (2009) M.-P. Gratacap et al. BLOOD
- Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy
- (2009) Alfonso Quintás-Cardama et al. CANCER
- Dasatinib treatment for Philadelphia chromosome-positive leukemias
- (2009) Hanna Jean Khoury et al. CANCER
- Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion
- (2009) Kimmo Porkka et al. CANCER
- Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily
- (2009) C. Sillaber et al. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
- Tuberculosis complicating imatinib treatment for chronic myeloid leukaemia
- (2009) J. M. A. Daniels et al. EUROPEAN RESPIRATORY JOURNAL
- Pancreatic enzyme elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure
- (2009) F. Palandri et al. HAEMATOLOGICA
- Ocular Side Effects Associated with Imatinib Mesylate and Perifosine for Gastrointestinal Stromal Tumor
- (2009) S. Serdar Dogan et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Peripheral neuropathy on imatinib treatment for chronic myeloid leukaemia: suspected adverse drug interaction with amlodipine
- (2009) INTERNAL MEDICINE JOURNAL
- Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
- (2009) Michele Baccarani et al. JOURNAL OF CLINICAL ONCOLOGY
- High-Dose Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: High Rates of Rapid Cytogenetic and Molecular Responses
- (2009) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial
- (2009) Jane F. Apperley et al. JOURNAL OF CLINICAL ONCOLOGY
- Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase
- (2009) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of Dasatinib Therapy in Patients With Early Chronic-Phase Chronic Myeloid Leukemia
- (2009) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 mg Versus 800 mg in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study
- (2009) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia
- (2009) A Hochhaus et al. LEUKEMIA
- Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy
- (2009) S Mustjoki et al. LEUKEMIA
- Nilotinib post-liver transplantation for acute hepatic failure related to imatinib
- (2009) Guilherme F. Perini et al. LEUKEMIA RESEARCH
- Hypolipemiant besides antileukemic effect of imatinib mesylate
- (2009) Radu Gologan et al. LEUKEMIA RESEARCH
- Renal failure associated with tyrosine kinase inhibitors—Case report and review of the literature
- (2009) Anat Gafter-Gvili et al. LEUKEMIA RESEARCH
- Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors
- (2009) Onder Tonyali et al. MEDICAL ONCOLOGY
- Partial Fanconi Syndrome Induced by Imatinib Therapy: A Novel Cause of Urinary Phosphate Loss
- (2008) Helene François et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Bullous Sweet Syndrome in a Patient With t(9;22)(q34;q11)-Positive Chronic Myeloid Leukemia Treated With the Tyrosine Kinase Inhibitor Nilotinib
- (2008) Kjell Matthias Kaune et al. ARCHIVES OF DERMATOLOGY
- Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient
- (2008) D Mattei et al. BONE MARROW TRANSPLANTATION
- Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis
- (2008) Hugues de Lavallade et al. BRITISH JOURNAL OF HAEMATOLOGY
- Sprycel for Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate
- (2008) M. Brave et al. CLINICAL CANCER RESEARCH
- Tasigna for Chronic and Accelerated Phase Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia Resistant to or Intolerant of Imatinib
- (2008) M. Hazarika et al. CLINICAL CANCER RESEARCH
- Immunomodulatory effects of imatinib and second-generation tyrosine kinase inhibitors on T cells and dendritic cells: an update
- (2008) R. Seggewiss et al. CYTOTHERAPY
- Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib
- (2008) A. Franceschino et al. HAEMATOLOGICA
- Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia
- (2008) D. H. Kim et al. HAEMATOLOGICA
- Reactivation of chronic hepatitis B infection related to imatinib mesylate therapy
- (2008) Shilen Lakhani et al. Hepatology International
- Optic disc edema as a possible complication of Imatinib mesylate (Gleevec)
- (2008) Soon-Il Kwon et al. JAPANESE JOURNAL OF OPHTHALMOLOGY
- Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia
- (2008) Neil P. Shah et al. JOURNAL OF CLINICAL ONCOLOGY
- Use of dasatinib in the patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia with resistance to imatinib and renal failure
- (2008) M. Sonmez et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- Gynecomastia in a male after dasatinib treatment for chronic myeloid leukemia
- (2008) G Caocci et al. LEUKEMIA
- Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib
- (2008) A Hochhaus et al. LEUKEMIA
- An evaluation of the cardiotoxicity of imatinib mesylate
- (2008) Antonio Luiz Ribeiro et al. LEUKEMIA RESEARCH
- Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib
- (2008) M. Breccia et al. LEUKEMIA RESEARCH
- Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia
- (2008) Sarah A. Holstein et al. LEUKEMIA RESEARCH
- Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia
- (2008) Walid Rasheed et al. LEUKEMIA RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now